INVESTORS & MEDIA
News Release
Christine A. Poon Elected to Regeneron Board of Directors
"Chris brings an incredibly important commercial perspective and deep strategic and operational knowledge of the pharmaceutical industry to our Board," said
"Throughout my career I have enjoyed the thrill of translating basic research ideas into products and services that could make a real difference to global health and wellness," said
"Now is an exciting time in Regeneron history as we await the results of several large Phase 3 programs," said
Ms. Poon became dean of the
Ms. Poon also is on the Board of Directors of
About Regeneron
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers. Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer. Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.
Forward Looking Statement
This news release includes forward-looking statements about Regeneron and its products, development programs, finances, and business, all of which involve a number of risks and uncertainties. These include, among others, risks and timing associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that are superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with
Astellas, the sanofi-aventis Group and
Contact Information: | ||
Michael Aberman, M.D. | Peter Dworkin | |
Investor Relations | Corporate Communications | |
914.345.7799 | 914.345.7800 | |
michael.aberman@regeneron.com | peter.dworkin@regeneron.com | |
SOURCE
News Provided by Acquire Media